Global genomics company BGI says that the company has produced more than 10 million of its RT-PCR Test for SARS-CoV-2 and is distributing them to more than 80 countries around the world, includingIndia,Indonesia,Thailand,Philippines,Brunei, andJapan.

BGI's Huo-Yan (Fire Eye) Laboratories have also been set up inAsia, US,Europe, and theMiddle East, bringing population-scale detection and diagnosis of COVID-19 to the world.

"The most critical thing for all of us at BGI is to help bring this pandemic under control. We are working with governments and institutions globally to achieve this mission," says Yin Ye, CEO of BGI Genomics, part of BGI Group. "We have more than trebled our production capacity to two million reactions a day to meet demand and expect to increase that again to three million reactions in the coming weeks."

In addition, BGI has donated over 130,000 test kits, while partner organizations have donated another 178,000 of BGI's test kits.

BGI is one of the few companies globally that has products recognized as officially approved for use in China, the European Union,the United States, andJapan. BGI's RT-PCR Test for SARS-CoV-2 has been granted approval by the US FDA Emergency Use Authorization,Europe'sCE-IVD,China'sNMPA andJapan's PMDA.

In addition, BGI has donated over 130,000 test kits, while partner organizations have donated another 178,000 of BGI's test kits.